The company’s product candidate is IDE196, a protein kinase C inhibitor that targets genetically defined cancers with GNAQ or GNA11 gene mutations. On April 15, analyst Jeet Mukherjee from BTIG ...

"These data presented at AACR represent our dedication in advancing liquid biopsy testing with our proprietary single molecule precision technology and setting new standards in what can be ...

The most advanced program, darovasertib, targets tumors with GNAQ/GNA11 mutations, showing promising clinical activity. With over $1 billion in cash and other investments, IDYA has 4–5 years of ...

The company’s product pipeline includes darovasertib (IDE196), a protein kinase C (PKC) inhibitor that targets cancers with GNAQ and GNA11 mutations. Ideaya develops small molecule inhibitors based on ...

Uveal melanoma (UM) is a rare and lethal malignancy with very limited therapeutic options characterized by mutually exclusive activating mutations in GNAQ and GNA11, resulting in overactive ...

While the activating R183Q GNAQ somatic mutation is the most common somatic mutation underlying SWS, recent research also implicates that GNA11 and GNB2 somatic mutations are related to SWS. Recent ...

In a market trending down, there are fewer scenarios more appealing to investors than ones outlining bearish sentiment is about to turn positive. And according to Ari Wald, head of technical ...

Cancer cells' genetic instability is characterized by chromosomal abnormalities. GNA11 and GNAQ are the most frequently mutated genes in UM. These genes are mutated in 71–93 % of all UM cancers.

IDEAYA is currently evaluating the combination of darovasertib, a PKC inhibitor, and crizotinib, a cMET inhibitor, in patients with MUM and in patients with GNAQ or GNA11 mutant skin melanoma in ...

Presently, Ideaya is analysing darovasertib and crizotinib combination in an ongoing Phase I/II clinical trial enrolling individuals with MUM and those with GNAQ or GNA11 mutant skin melanoma. This ...

Cherry angiomas are diagnosed clinically according to visual characteristics. Another diagnostic tool is optical coherence tomography, which helps determine the depth and extent of CAs and whether ...

Research paper: 'Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause’. Zhou et al. Nature Genetics. DOI 10.1038/s41588-021 ...